|
Actavis launches three new generic products in Europe |
|
|
|
30 May 2006 |
The drugs include Sumatriptan, used to treat migraine headaches, the atypical antipsychotic Risperidone and Granisetron, the anti-nausea drug.
REYKJAVIK, Iceland | May 29, 2006 | Actavis Group (ICEX: ACT), the international generic pharmaceuticals company, announces that it is one of the first to launch three new generic products into a number of key European markets including Germany, the UK, Hungary and Poland. The drugs include Sumatriptan, used to treat migraine headaches, the atypical antipsychotic Risperidone and Granisetron, the anti-nausea drug.
The new drugs have been developed in Actavis' in-house R&D facilities in Iceland and Malta and by Actavis' partners in India. Sumatriptan is one of the most widely sold migraine drugs in the world and has been used to treat millions of patients for years with good results. Risperidone is used to treat delusional psychosis, including schizophrenia, and some forms of bipolar disorder and psychotic depression. Granisetron reduces nausea and vomiting, common adverse effects associated with chemotherapy.
Each of these products will be marketed by Actavis' European sales force and through Medis, Actavis' third party sales division, who will distribute the drugs to their customers on the Continent.
Commenting, Gudbjorg Edda Eggertsdottir, Executive Vice President of Third Party Sales said:
"Actavis has one of the largest product pipelines in the industry with close to three hundred drugs under development and registration today. We have already introduced over one hundred new products into different markets this year underlining our ability to bring new drugs to the market on patent expiry. The products we are launching will support our strong portfolio in these markets, but are not expected to be among the Group's highest selling products in 2006."
For further information please contact:
Halldor Kristmannsson, VP, Corporate Communications
Tel: (+354) 535 2300 / (+354) 840 3425
Email:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
SOURCE: Actavis Group |
